Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1996 June; 73(12): 1498–1502.
PMCID: PMC2074539

Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.


To assess the role of hepatitis B e antigen (HBeAg) and its interaction with hepatitis B surface antigen (HBsAg) on the development of hepatocellular carcinoma (HCC), this case-control study included 361 age- and sex-matched pairs of patients with histologically proven HCC and healthy control subjects. HBsAg, HBeAg and antibody to HBeAg (anti-HBe) were detected by radioimmunoassay. Antibodies to hepatitis C virus (anti-HCV) were detected by second-generation enzyme immunoassay. The prevalences of HBeAg (20.2%), HBsAg (80.3%) and anti-HCV (29.5%) in cases were higher than in controls (1.9%, 20.7%, and 2.7% respectively; each P < 0.0001). Using patients negative for HBsAg, HBeAg and anti-HBe as a referent group, univariate analysis indicated that HBsAg alone or HBsAg and HBeAg were risk factors for HCC (P for trend < 0.0001). Calculation of incremental odds ratio indicated that there was additive interaction between HBsAg and HBeAg. Multivariate analysis indicated that HCC development was strongly associated with the presence of HBeAg (odds ratio, 8.1; 95% confidence interval, 2.4-27.1), HBsAg (odds ratio, 68.4; 95% confidence interval, 20.5-227.8) and anti-HCV (odds ratio, 59.3; 95% confidence interval, 13.6-258.4). In conclusion, HBsAg, HBeAg and anti-HCV are independent risk factors for HCC. There is additive and independent effect modification between HBsAg and HBeAg on the development of HCC.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (936K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, Chang WY, Sheen MC, Lin TM. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991 Mar;13(3):398–406. [PubMed]
  • Chen CJ, Tseng SF, Lu CF, Lin HC, You SL, Chen CS, Hwang SJ, Hsieh SF, Hsu ST. Current seroepidemiology of hepatitis D virus infection among hepatitis B surface antigen carriers of general and high-risk populations in Taiwan. J Med Virol. 1992 Oct;38(2):97–101. [PubMed]
  • Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):470–475. [PubMed]
  • Chen DS, Lai MY, Sung JL. Delta agent infection in patients with chronic liver diseases and hepatocellular carcinoma--an infrequent finding in Taiwan. Hepatology. 1984 May-Jun;4(3):502–503. [PubMed]
  • Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature. 1983 Mar 3;302(5903):21–24. [PubMed]
  • Jeng JE, Tsai JF. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol. 1991 May;34(1):74–77. [PubMed]
  • Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984 May;4(2):136–146. [PubMed]
  • Leung NW, Tam JS, Lau GT, Leung TW, Lau WY, Li AK. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer. 1994 Feb 15;73(4):1143–1148. [PubMed]
  • Lin TM, Chen CJ, Lu SN, Chang AS, Chang YC, Hsu ST, Liu JY, Liaw YF, Chang WY. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res. 1991 Nov-Dec;11(6):2063–2065. [PubMed]
  • Popper H, Thung SN, McMahon BJ, Lanier AP, Hawkins I, Alberts SR. Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. Arch Pathol Lab Med. 1988 May;112(5):498–504. [PubMed]
  • Raimondo G, Campo S, Smedile V, Rodinò G, Sardo MA, Brancatelli S, Villari D, Pernice M, Longo G, Squadrito G. Hepatitis B virus variant, with a deletion in the preS2 and two translational stop codons in the precore regions, in a patient with hepatocellular carcinoma. J Hepatol. 1991;13 (Suppl 4):S74–S77. [PubMed]
  • Schirmacher P, Rogler CE, Dienes HP. Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63(2):71–89. [PubMed]
  • Thomas HC, Carman WF. Envelope and precore/core variants of hepatitis B virus. Gastroenterol Clin North Am. 1994 Sep;23(3):499–514. [PubMed]
  • Tsai JF, Margolis HS, Fields HA, Chang WY, Tsai JH. Hepatitis delta virus superinfection among patients with chronic hepatitis B in southern Taiwan. Scand J Infect Dis. 1990;22(4):403–405. [PubMed]
  • Tsai JF, Tsai JH, Chang WY. Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Gastroenterol Jpn. 1990 Jun;25(3):388–393. [PubMed]
  • Tsai JF, Tsai JH, Chang WY, Ton TC. Elevation of circulating immune complexes and its relationship to alpha-fetoprotein levels in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Cancer Invest. 1991;9(2):137–143. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Tsai JH. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol. 1993 Dec;41(4):296–300. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver. 1994 Apr;14(2):98–102. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer. 1994 Jun;69(6):1157–1159. [PMC free article] [PubMed]
  • Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case-control study. Int J Cancer. 1994 Mar 1;56(5):619–621. [PubMed]
  • Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis C. J Med Virol. 1995 May;46(1):12–17. [PubMed]
  • Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine (Baltimore) 1995 May;74(3):136–143. [PubMed]
  • Tsai JF, Margolis HS, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol. 1995 Apr;75(1):39–44. [PubMed]
  • Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. Br J Cancer. 1995 Aug;72(2):442–446. [PMC free article] [PubMed]
  • Zaman S, Khan M, Alam K, Williams R. Primary hepatocellular carcinoma and viral hepatitis B and C infection in Bangladeshi subjects. J Trop Med Hyg. 1995 Feb;98(1):64–68. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK